03 · Outlook

Outlook

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 2 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Outlook across your briefs

Our 30, 60 and 90 day view is unchanged from Thursday: rates and a falling market may be the main risk, while drugmakers keep licensing early platforms.

HorizonWhat we expectWhat would change itOdds
30 daysGoal dates on 11.22, 11.27 and 11.30, the CMS negotiated prices due by 11.30 and the 12.09 FOMC, where a hike is priced in futures, as reported, set the news flowA hold or a 50 basis point move at the 12.09 FOMC·
60 daysSUO (12.02), ASH (12.12 to 12.15) and year-end goal dates lead the calendarA biopharma acquisition of $5B or more (call 9 in 15)·
90 daysRAS drugs in pancreatic cancer may draw more first-line data and trials, with randomized results still aheadA further rise in the 10-year yield, now 5.04%·

Dates from 14 Verified Catalyst Calendar; odds only where a logged call in 15 sets them. Analysis

RED TEAM

Our outlook has not moved while the market fell six days running, as reported. If the sell-off spreads, the risk to small biotech may be larger than our rates line suggests. Analysis